APS.TO - Aptose Biosciences Inc.
| Previous Close | 8.68 |
| Open | 8.72 |
| Bid | 8.72 x 0 |
| Ask | 8.78 x 0 |
| Day's Range | 8.54 - 8.86 |
| 52 Week Range | 2.37 - 12.24 |
| Volume | 42,481 |
| Avg. Volume | 105,243 |
| Market Cap | 662.785M |
| Beta (5Y Monthly) | 1.00 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.52 |
| Earnings Date | Mar. 09, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
- The Motley Fool
Market Crash Lessons: 3 Stocks That Show Cash Is King
Holding on to cash is a necessity for almost all businesses. Not all companies do, and it's a mistake, which many of the companies will pay for in the crash.The post Market Crash Lessons: 3 Stocks That Show Cash Is King appeared first on The Motley Fool Canada.
- Thomson Reuters StreetEvents
Edited Transcript of APS.TO earnings conference call or presentation 10-Mar-20 9:00pm GMT
Q4 2019 Aptose Biosciences Inc Earnings Call
- GlobeNewswire
Aptose Reports Results for the Fourth Quarter and Full Year 2019
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results for the year and three months ended December 31, 2019 and reported on corporate developments. Based on current operations, we expect that cash on hand and available capital provide the Company with sufficient resources to fund all planned Company operations including research and development into early 2022.
- GlobeNewswire
Aptose to Release Fourth Quarter and Year End December 31, 2019 Financial Results and Hold Conference Call on March 10, 2020
SAN DIEGO and TORONTO, Feb. 25, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.
- Zacks
Are Options Traders Betting on a Big Move in Aptose (APTO) Stock?
Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.
- Baystreet
ATCO, Algonquin, Aptose at 52-Week Highs
ATCO Ltd. (T.ACO.X) hit a new 52-week high of $52.95 Tuesday. No news announcements today. Aptose ...
- Baystreet
Seven Aces, Alpha, Aptose at 52-week Highs
Seven Aces Limited (V.ACES) hit a new 52-week high of $1.39 Friday. No news announcements today. Alpha ...
- GlobeNewswire
Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference
SAN DIEGO and TORONTO, Jan. 29, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.
- GlobeNewswire
Aptose Biosciences to Present at Biotech Showcase™ 2020 Conference
SAN DIEGO and TORONTO, Jan. 07, 2020 -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.
- The Motley Fool
Fear a Recession in 2020? Buy This Cheap Biotech Stock
If Aptose Biosciences Inc (TSX:APS) is successful at treating life-threatening cancers, the stock could see a huge increase in value, and shareholders will be richly rewarded.
- Baystreet
Atrium, Balmoral, CT at 52-Week Highs
Atrium Mortgage Investment Corporation (T.AI) hit a new 52-week high of $14.43 Monday. No news announcements ...
- GlobeNewswire
Aptose Announces Closing of Public Offering of Common Shares
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering of 18,543,750 common shares (the “Offering”) at the public offering price of US$4.00 per share. The number of shares sold includes the full exercise by the underwriters of their option to purchase additional common shares in the Offering. Gross proceeds from the Offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Aptose, are approximately US$74.2 million.
- GlobeNewswire
Aptose Announces Pricing of Public Offering of Common Shares
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it priced its previously announced underwritten public offering of 16,125,000 common shares (the “Offering”) at a price of US$4.00 per share. Gross proceeds from the Offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Aptose, are expected to be approximately US$64.5 million. The underwriters have been granted a 30-day option to purchase up to an additional 2,418,750 common shares in the Offering, under the same terms and conditions.
- GlobeNewswire
Aptose Announces Proposed Public Offering of Common Shares
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has commenced an underwritten public offering of its common shares (the “Offering”). In addition, Aptose intends to grant the Underwriters a 30-day option to purchase up to an additional 15% of the common shares offered in the Offering. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the offering.
- GlobeNewswire
Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting
SAN DIEGO and TORONTO, Dec. 09, 2019 -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics.
- GlobeNewswire
Aptose Presents Highlights From Corporate Event At ASH
SAN DIEGO, TORONTO and ORLANDO, Fla., Dec. 07, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) released highlights from a corporate event and clinical update today.
- GlobeNewswire
Aptose Appoints Rafael Bejar, M.D., Ph.D., as Chief Medical Officer
Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of Rafael Bejar, M.D., Ph.D., to the position of Senior Vice President, Chief Medical Officer, effective January 1, 2020. In his role as a member of the executive leadership team, Dr. Bejar will oversee global clinical development and regulatory initiatives for Aptose, as well as other research activities. “Rafael is a physician-scientist whose depth of experience both in the research setting and in treating patients with hematologic malignancies brings a unique and important perspective as we accelerate the clinical development of our hematologic product candidates,” said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer.
- GlobeNewswire
Aptose to Present at 31st Annual Piper Jaffray Healthcare Conference
SAN DIEGO and TORONTO, Dec. 02, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.
- Thomson Reuters StreetEvents
Edited Transcript of APS.TO earnings conference call or presentation 5-Nov-19 10:00pm GMT
Q3 2019 Aptose Biosciences Inc Earnings Call
- Simply Wall St.
Is Aptose Biosciences (TSE:APS) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- GlobeNewswire
Aptose to Present at BIO-Europe Conference
SAN DIEGO and TORONTO, Nov. 07, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the.
- GlobeNewswire
Aptose to Present New CG-806 Data at the 2019 ASH Annual Meeting
– Company to Hold Event During ASH – – CG-806 Preclinical Abstracts Accepted for Presentation – SAN DIEGO and TORONTO, Nov. 06, 2019 -- Aptose Biosciences Inc. (“Aptose”).
- GlobeNewswire
Aptose Reports Results for the Third Quarter Ended September 30, 2019
CG-806 Mutation Agnostic FLT3/BTK Inhibitor and APTO-253 MYC Inhibitor Safely Dose Escalate CLL Patient Treated with Second Dose Level of CG-806 Shows Evidence of Clinical.
- GlobeNewswire
Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019
SAN DIEGO and TORONTO, Oct. 22, 2019 -- Aptose Biosciences Inc. (NASDAQ: APTO; TSX: APS), a clinical-stage biotechnology company developing first-in-class agents that target.
